GENEVA—The World Health Organization will resume its trial of hydroxychloroquine for potential use against the CCP virus, its chief said on Wednesday, after those running the study briefly stopped giving it to new patients over health concerns.
The UN agency last month paused the part of its large study of treatments against COVID-19 in which newly enrolled patients were getting the anti-malarial drug to treat COVID-19 due to fears it increased death rates and irregular heartbeats.
